1. Ilott I, Rick J, Patterson M, Turgoose C, Lacey A. What is protocol-based care? A concept analysis. J Nurs Manag. 2006;14(7):544-52. doi: 10.1111/j.1365-2934.2006.00703.x.

2. Gulwani S. Programming by examples: Applications, algorithms, and ambiguity resolution.Redmond, WA: Microsoft Corporation; 2016..

3. Jun G, Ward J, Morris Z, Clarkson J. Health care process modelling: which method when? Int J Qual Health Care. 2009;21(3):214- 24. doi: 10.1093/intqhc/mzp016.

4. Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009;6(7):e1000097. doi: 10.1371/journal.pmed.1000097.

5. Fanouriakis A, Tziolos N, Bertsias G, Boumpas DT. Update οn the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis. 2021;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272.

6. Pons-Estel BA, Bonfa E, Soriano ER, Cardiel MH, Izcovich A, Popoff F, et al. First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of Rheumatology (PANLAR). Ann Rheum Dis. 2018;77(11):1549-57. doi: 10.1136/annrheumdis-2018-213512.

7. Carter EE, Barr SG, Clarke AE. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol. 2016;12(10):605-20. doi: 10.1038/nrrheum.2016.137.

8. Londoño J, Peláez Ballestas I, Cuervo F, Angarita I, Giraldo R, Rueda JC, et al. Prevalencia de la enfermedad reumática en Colombia, según estrategia COPCORD-Asociación Colombiana de Reumatología. Estudio de prevalencia de enfermedad reumática en población colombiana mayor de 18 años. Rev Colomb Reumatol. 2018;25(4):245-56. doi: 10.1016/j.rcreu.2018.08.003.

9. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. Best Pract Res Clin Rheumatol. 2018;32(2):188-205. doi: 10.1016/j.berh.2018.09.004.

10. Frieri M. Mechanisms of disease for the clinician: systemic lupus erythematosus. Ann Allergy Asthma Immunol. 2013;110(4):228-32. doi: 10.1016/j.anai.2012.12.010.

11. Ruis-Santacruz OO, Londoño-Patiño JD, Vélez-Sánchez P, Ortiz-Álvarez ID, Motta LF, Valle-Oñate RR. Descripción de una cohorte de pacientes con Lupus Eritematoso Sistémico (LES) en un Hospital de Bogotá-Colombia. Rev Colomb Reumatol. 2003;10(4):12.

12. Bosch X, Formiga F, López-Soto A. Lupus eritematoso sistémico en el anciano. Rev Esp Geriatría Gerontol. 2012;47(2):71-5. doi: 10.1016/j.regg.2011.11.005.

13. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey‐Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol. 2019;71(9):1400-12. doi: 10.1002/art.40930.

14. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-86. doi: 10.1002/art.34473.

15. Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol. 2002;29(2):288-91.

16. van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958-67. doi: 10.1136/annrheumdis-2013-205139.

17. Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis. 2019;78(6):736-45. doi: 10.1136/annrheumdis-2019-215089.

18. Brouwers MC, Kerkvliet K, Spithoff K; AGREE Next Steps Consortium. The AGREE Reporting Checklist: a tool to improve reporting of clinical practice guidelines. BMJ. 2016;i1152. doi: 10.1136/bmj.i1152.

19. Fanouriakis A, Kostopoulou M, Cheema K, Anders HJ, Aringer M, Bajema I, et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79(6):713-23. doi: 10.1136/annrheumdis-2020-216924.

20. Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S, et al. Canadian Rheumatology Association Recommendations for the Assessment and Monitoring of Systemic Lupus Erythematosus. J Rheumatol. 2018;45(10):1426-39. doi: 10.3899/jrheum.171459.

21. Trujillo-Martín MM, Rúa-Figueroa Fernández de Larrinoa I, Ruíz-Irastorza G, Pego-Reigosa JM, Sabio Sánchez JM, Serrano-Aguilar P. Guía de práctica clínica para el lupus eritematoso sistémico: recomendaciones para el abordaje clínico general. Med Clin (Barc). 2016;146(9):413.e1-413.e14. dx.doi.org/10.1016/j.medcli.2016.01.013.

22. Xibillé-Friedmann D, Pérez-Rodríguez M, Carrillo-Vázquez S, Álvarez-Hernández E, Aceves FJ, Ocampo-Torres MC, et al. Guía de práctica clínica para el manejo del lupus eritematoso sistémico propuesta por el Colegio Mexicano de Reumatología. Reumatol Clínica. 2019;15(1):3-20. doi: 10.1016/j.reuma.2018.03.011.

23. Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D’Cruz D, et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults. Rheumatology (Oxford). 2018;57(1):e1-45. doi: 10.1093/rheumatology/kex286.

24. Ceccarelli F, Perricone C, Massaro L, Pacucci VA, Cipriano E, Truglia S, et al. The role of disease activity score 28 in the evaluation of articular involvement in systemic lupus erythematosus. ScientificWorldJournal.. 2014;2014:236842. doi: 10.1155/2014/236842.

25. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-276. doi: 10.1016/j.kint.2021.05.021.

26. Sayani FA, Abrams CS. How I treat refractory thrombotic thrombocytopenic purpura. Blood. 2015;125(25):3860-7. doi: 10.1182/blood-2017-08-803171.

27. Beloncle F, Buffet M, Coindre JP, Munoz-Bongrand N, Malot S, Pène F, et al. Splenectomy and/or cyclophosphamide as salvage therapies in thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Transfusion. 2012;52(11):2436-44. doi: 10.1111/j.1537-2995.2012.03578.x.

28. Martínez M, Sánchez AI, Martínez MP, Miró E. Psychological treatment in patients with systemic lupus erythematosus: A systematic review. Terapia Psicológica. 2016;34(3):167-81. doi: 10.4067/S0718-48082016000300001.

29. Kwo PY, Cohen SM, Lim JK. ACG Clinical Guideline: Evaluation of Abnormal Liver Chemistries. Am J Gastroenterol. 2017;112(1):18-35. doi: 10.1038/ajg.2016.517.

30. New York Heart Association (NYHA). Diseases of the Heart and Blood Vessels. Nomenclature and Criteria for diagnosis. 6th ed. Boston: Little, Brown and Co.; 1964.

31. Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43(38):3618-3731. doi: 10.1093/eurheartj/ehac237.

32. García F, Álvarez M, Bernal C, Chueca N, Guillot V. Diagnóstico de laboratorio de la infección por el VIH, del tropismo viral y de las resistencias a los antirretrovirales. Enferm Infecc Microbiol Clínica. 2011;29(4):297-307. doi: 10.1016/j.eimc.2010.12.006.

33. Flores-Ibarra AA, Ochoa-Vázquez MD, Tec GAS. Estrategias diagnósticas aplicadas en la Clínica de Tuberculosis del Hospital General Centro Médico Nacional la Raza. Rev Med Inst Mex Seguro Soc. 2016;54(1);122-7.

34. Carrasco-Álvarez RI. Interpretación de las pruebas diagnósticas de sífilis en gestantes. Rev Peru Ginecol Obstet. 2018;64(3):345-52.

35. Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, et al. 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2022; ard-2022-223335. doi: 10.1136/ard-2022-223335.

36. Medina-Orjuela A, Rosero-Olarte Ó, Rueda-Plata PN, Sánchez-Escobar F, Chalem-Choueka M, González-Reyes MA, et al. II Consenso Colombiano para el Manejo de la Osteoporosis Posmenopáusica. Rev Colomb Reumatol. 2018;25(3):184-210. doi: 10.1016/j.rcreu.2018.02.006.

37. Barnes JN, Tanaka H. Cardiovascular benefits of habitual exercise in systemic lupus erythematosus: a review. Phys Sportsmed. 2012;40(3):43-8. doi: 10.3810/psm.2012.09.1980.

38. Tselios K, Urowitz MB. Cardiovascular and Pulmonary Manifestations of Systemic Lupus Erythematosus. Curr Rheumatol Rev. 2017;13(3):206-218. doi: 10.2174/1573397113666170704102444.

39. Gwinnutt JM, Wieczorek M, Cavalli G, Balanescu A, Bischoff-Ferrari HA, Boonen A, et al. Effects of physical exercise and body weight on disease-specific outcomes of people with rheumatic and musculoskeletal diseases (RMDs): systematic reviews and meta-analyses informing the 2021 EULAR recommendations for lifestyle improvements in people with RMDs. RMD Open. 2022;8(1):e002168. doi: 10.1136/rmdopen-2021-002168.

40. Yusuf IH, Foot B, Lotery AJ. The Royal College of Ophthalmologists recommendations on monitoring for hydroxychloroquine and chloroquine users in the United Kingdom (2020 revision): executive summary. Eye (Lond). 2021;35(6):1532-7. doi: 10.1038/s41433-020-01380-2.